Scholar Rock Holding (SRRK) Profit After Tax (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Profit After Tax of -$105.5 million for Q1 2026, down 41.2% year-over-year from -$179.4 million in Q1 2025, and down 458639.13% quarter-over-quarter from -$23000.0 in Q4 2025.
Scholar Rock Holding (SRRK) Profit After Tax (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Profit After Tax history runs 10 years deep, the most recent figure standing at -$105.5 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 41.2% year-over-year to -$105.5 million; the TTM figure through Mar 2026 stood at -$317.7 million (down 60.73% YoY), while the FY2025 annual figure was -$66000.0, down 197.06% from the prior year.
- Profit After Tax for Q1 2026 stood at -$105.5 million, down from -$23000.0 in the prior quarter.
- The five-year high for Profit After Tax was $32000.0 in Q4 2024, with the low at -$110.0 million in Q2 2025.
- The 5-year median for Profit After Tax is -$44.0 million (2022), against an average of -$51.4 million.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax tumbled 395.33% in 2023, then jumped 100.07% in 2024.
- Scholar Rock Holding's Profit After Tax stood at -$39.2 million in 2022, then declined by 19.86% to -$47.0 million in 2023, then surged by 100.07% to $32000.0 in 2024, then plunged by 171.88% to -$23000.0 in 2025, then slumped by 458639.13% to -$105.5 million in 2026.
- Business Quant data shows SRRK's Profit After Tax at -$105.5 million in Q1 2026, -$23000.0 in Q4 2025, and -$102.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | -109.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -109.90 Mn |
| Mar 31, 2026 | -105.51 Mn |
| Dec 31, 2025 | -23,000.00 |
| Sep 30, 2025 | -102.16 Mn |
| Jun 30, 2025 | -110.03 Mn |
| Mar 31, 2025 | -74.72 Mn |
| Dec 31, 2024 | 32,000.00 |
| Sep 30, 2024 | -64.48 Mn |
| Jun 30, 2024 | -58.51 Mn |
| Mar 31, 2024 | -56.85 Mn |
| Dec 31, 2023 | -46.99 Mn |
| Sep 30, 2023 | -42.36 Mn |
| Jun 30, 2023 | -37.93 Mn |
| Mar 31, 2023 | -39.38 Mn |
| Dec 31, 2022 | -39.20 Mn |
| Sep 30, 2022 | -43.30 Mn |
| Jun 30, 2022 | -44.00 Mn |
| Mar 31, 2022 | -7.95 Mn |
| Dec 31, 2021 | 95.85 Mn |
| Sep 30, 2021 | -37.51 Mn |